当前位置：   首页 > 需求大厅

【基本信息】 需要 受试者类型 ： 健康受试者 性 别 ： 不限 婚 姻 状 况 ： 不限 适 应 专 业 ： 药物适应症： 神经保护药 招 募 人 数： 70人 试验起止日期 ： 2014-11-25 -- 2015-01-29 报名截止日期 ： 2015-01- 14 补 偿 金 ： ￥2000 【项目描述】 苏州医院需招募男女健康受试者 药物名称：索法地尔 二期 隶属：消炎保护药 补偿金额：2000元 要求：5男5女 年龄19-35周岁 身体指标19-30 绝对安全；住院免费提供一日三餐 空调 热水器 24小时开放 电视 wifi 麻将 扑克 时间安排下周体检直接入住 入住3天 2次随访 给药第7天和14天2次随访 总时间为2周期 报名电话：18021275657 或QQ群424267082 【入选标准】 苏州医院需招募男女健康受试者 药物名称：索法地尔 二期 隶属：消炎保护药 补偿金额：2000元 要求：5男5女 年龄19-35周岁 身体指标19-30 绝对安全；住院免费提供一日三餐 空调 热水器 24小时开放 电视 wifi 麻将 扑克 时间安排下周体检直接入住 入住3天 2次随访 给药第7天和14天2次随访 总时间为2周期 报名电话：18021275657 或QQ群424267082 【排除标准】 【研究中心列表】 苏州 苏州大学附属第一人民医院 【联系方式】 联系人 ： 施尘 手 机 ： 18021275657   [更多]

发布日期：2014-11-18 距离报名截止还有33天 【基本信息】 需要 受试者类型 ： 健康受试者 性 别 ： 不限 婚 姻 状 况 ： 不限 适 应 专 业 ： 药物适应症： 癫痫辅助用药 招 募 人 数： 24人 试验起止日期 ： 2014-12-25 -- 2015-02-25 报名截止日期 ： 2015-01- 25 补 偿 金 ： ￥1800 【项目描述】 两制剂双周期交叉试验评价药物的生物等效性 【入选标准】 仅招募健康志愿者（男、女性均可），18～45岁，女性妊娠试验阴性。 纳入标准： 1. 年龄：18-45岁。 2. 体重：同一批受试者体重(kg)不宜悬殊过大。一般要求体重指数[BMI＝体重(kg)/身高(M)2]在 19～26范围内。 3. 根据既往病史、体检和常规实验室检查数据证明受试者健康；排除心、肺、肝、肾、消化、血 液、神经、代谢异常和精神、神经等病史的可能性。 4. .两周前未服用其他任何药物 5. 了解试验目的、试验步骤、试验药物的药理特性及可能发生的不良反应，自愿作为受试者。 6. 受试者签署知情同意书　 7. 在临床研究开始前，研究者应向受试者充分解释本研究目的、试验药物的主要药理作用、可能 发生的不良反应与受试者的权益等有所了解，实验方法、试验的周期，观察指标、方法、应进行的体格 检查、可能受益与伤害等。在获得每个参加本临床研究的受试者同意（签名）后方可开始临床研究。 【排除标准】 【研究中心列表】 南京 鼓楼医院 【联系方式】 联系人 ： 肖大伟 办 公 电 话： 025-83107082   [更多]

【基本信息】 需要 受试者类型 ： 健康受试者 性 别 ： 不限 婚 姻 状 况 ： 不限 适 应 专 业 ： 药物适应症： 健康志愿者 招 募 人 数： 24人 试验起止日期 ： 2014-02-08 -- 2015-01-01 报名截止日期 ： 2015-01- 01 补 偿 金 ： ￥1000 【项目描述】 医院直接招募，项目均经筛选，安全性相对较好。地点在广州，地铁一号线附近 【入选标准】 年龄18-30，体重指数19-24且体重在50kg以上。服从安排，全程入住，禁烟酒等。 【排除标准】 【研究中心列表】 广州 广州市某三甲医院 【联系方式】 联系人 ： 张药师 手 机 ： 13725213684 办 公 电 话： 020-81268052   [更多]

苦木的化学成分研究资料------在苦木中分离的化合物，要有具体的分离方法，每个化合物有原始打印的H谱和C谱，有紫外红外更好。有这些资料的联系我，高价格商谈！   [更多]

（1）4-甲氧基-5羟基-铁屎米酮 cas：18110-86-6 （2）4，5-二甲氧基铁屎米酮 cas:18110-87-7 (3) 3-甲基-铁屎米酮-2,6-二酮 有做过苦木生物碱分离的研究生，手里有标准品的我们可以购买，如果能给我们分离也可以，需求量每种40-60mg。价格我们商谈！价钱好说   [更多]

勃林格殷格翰公司对诊断和治疗慢性阻塞性肺疾病以及重症哮喘患者新方法非常感兴趣。针对慢性阻塞性肺病患者或重症哮喘所造成的呼吸道障碍，他们积极寻求恢复方法并寻找分子靶点开发治疗药物。具体如下：（https://www.innocentive.com/ar/challenge/9933560） Boehringer Ingelheim (the Seeker) is interested in identifying new therapeutic concepts for the treatment of patients with chronic obstructive pulmonary disease (COPD) or severe asthma. The Seeker is specifically searching for molecular targets to develop therapeutic agents for the restoration of the airway epithelial barrier function in patients with COPD or severe asthma. The Seeker is also interested in molecular targets driving the regeneration of the airway epithelium. Submitted solutions that meet the Solution Requirements according to this InnoCentive Challenge Statement will be considered for up to three awards of $15,000 each. However, the Seeker may (i) not award any solution if none of the submitted proposals meets all Solution Requirements or (ii) award only the solution of the highest overall quality with $15,000. The consideration for an award requires the willingness and ability of the Solver to provide the Seeker with a non-exclusive license regarding all intellectual property related to the Challenge according to the terms of the InnoCentive Theroretical (Non-Exclusive-License) Challenge-Specific Agreement. 2. Additional application for Research Funding In addition to consideration for the award(s) Solvers with appropriate qualifications and expertise having access to a suitable research laboratory and equipment can apply for research funding (“Research Funding”) to execute a research plan that is proposed in the submitted solution. The requested funding should not exceed a funding period of 2 years and a total budget of $200,000. The selection of candidates for Research Funding will be conducted after completion of the Challenge, and will require the submission of additional information. The decision to fund research will be at the sole discretion of the Seeker. The Challenge according to No.   [更多]

我们对治疗克罗恩病和溃疡性结肠炎的新的机理和作用点感兴趣，这些可能包括，但不限于，接近病灶或调节菌群，代谢，遗传，后天产生的抗体。新治疗方法可能包括，但不限于，疫苗，基因治疗，和小分子化合物，而免疫抑制除外。理想的途径是先找到IBD发病新机理，再转化为一种治疗新的方法。具体如下：（https://www.innocentive.com/ar/challenge/9933446） Novel Treatment Approaches to Cure Inflammatory Bowel Diseases TAGS: Nature, Chemistry, Life Sciences, Ideation AWARD: $10,000 USD | DEADLINE: 2/16/15 | ACTIVE SOLVERS: 21 | POSTED: 12/16/14 The Seeker for this Challenge desires proposals describing potential approaches for curing Crohn’s disease and ulcerative colitis. The Seeker is interested in novel mechanisms of action that specifically address the pathogenesis of inflammatory bowel diseases (IBD). These may include, but are not limited to, approaches targeting or modulating the microbiota, metabolism, genetic, and epigenetic targets. Platforms may involve, but are not limited to, vaccines, gene therapy, and small molecule compounds. The Seeker is not interested in immunosuppression. Desirable approaches are specifically relevant to the pathogenesis of IBD and can be translated into a cure. This is an Ideation Challenge with a guaranteed award for at least one submitted solution. In addition to the Challenge award, the Seeker is open to establishing potential collaborations with the winning Solver(s) to further investigate proposed mechanisms with the eventual goal of developing a cure for IBD. Source: InnoCentive Challenge ID: 9933446 Challenge Overview The Seeker for this Challenge desires proposals for novel approaches that specifically address the causes of inflammatory bowel diseases (IBD) to enable the development of a cure. The Seeker is interested in unique ideas and new approaches (including gene delivery techniques), but is not interested in approaches that are simply common targets for various immunological conditions. That is, the approach must be specifically relevant to the pathogenesis of IBD and can be translated into a cure. This is an Ideation Challenge, which has   [更多]

Sibutramine的生产工艺   [更多]

重性抑郁障碍（MDD）是一种使人衰弱的精神障碍，在美国约有20000000流行病例。然而不同的抗抑郁药可用于治疗不同的抑郁症，，约50%的抑郁症患者的初始治疗结果不理想。最近有证据表明，在发病的几个小时内氯胺酮给药治疗难治性抑郁症已经显著有所改善。勃林格殷格翰公司寻找氯胺酮在人体中反应和持续的抗抑郁作用的机理。 Boehringer Ingelheim Challenge: Understanding the Antidepressant Effect of Ketamine TAGS: Nature, Chemistry, Life Sciences, Ideation AWARD: $21,000 USD | DEADLINE: 1/15/15 | ACTIVE SOLVERS: 20 | POSTED: 12/15/14 1. The Challenge and qualification for the award Major depressive disorder (MDD) is a debilitating psychiatric disorder with about 20 million prevalent cases in the United States. Various antidepressants are available for treatment of patients suffering from MDD, however, about 50% of MDD patients do not respond adequately to initial treatments. Recent evidence shows that ketamine administered to patients with treatment resistant depression has resulted in marked improvement within hours of treatment. Boehringer Ingelheim (the Seeker) desires a working hypothesis for ketamine’s mechanism of action and sustained antidepressant effect. The submitted solutions will be considered for the award. There will be a guaranteed award for at least one submitted solution. The total payout will be $21,000, with at least one award being no smaller than $12,000 and no award being smaller than $3,000. 2. Additional application for Research Funding In addition to consideration for the award for the submitted Solutions, Solvers with appropriate qualifications and expertise having access to a suitable research laboratory and equipment can apply for research funding (“Research Funding”) to execute a research plan that is proposed in the Solution. The requested funding should not exceed a funding period of 2 years and a total budget of $200,000. The selection of candidates for Research Funding will be conducted after completion of this Challenge, and will require the submission of additional information. The decision to fund research will be at the discretion of the Seeker.   [更多]

可使生物降解的长效制剂微胶囊技术是一种药物控释技术。在授控的较长的一段时间药物缓慢释放。在过去的二十年中，武田公司已经完善了其专有技术，即具有微胶囊的长效制剂，能在人体的6个多月保持血药浓度。武田希望能有一种技术，即在确定的治疗药物，使用缓释长效制剂微胶囊技术能在任何人体组织上定向使用。具体如下：{https://www.innocentive.com/ar/challenge/9933674} AWARD: varies | DEADLINE: 1/26/15 | ACTIVE SOLVERS: 28 | POSTED: 12/10/14 Depot formulation using a biodegradable microcapsule is one technique for the controlled delivery of pharmaceuticals. The drug is slowly released over an extended period of time in a controlled manner. During the past two decades, Takeda has perfected its proprietary technology, which features a microcapsule depot formulation that maintains drug plasma levels for more than 6 months in humans. Takeda wishes to identify therapeutic agents that will benefit from sustained release through depot formulation using microcapsule technology. This is an electronic Request-for-Partners (eRFP) Challenge; the Solver will only need to submit a written proposal to be evaluated by the Seeker with a goal of establishing a Takeda funded collaborative partnership. A finder’s fee of $3,000 will be offered at the Seeker’s sole discretion to submission(s) that provide contacts which meet the criteria of the Challenge. Source: InnoCentive Challenge ID: 9933674 Challenge Overview Takeda is well known for its superior depot formulation using microcapsule technology. Controlled sustained release of drugs is achieved using either PLGA (poly-lactic-co-glycolic acid) or PLA (poly-lactic acid) polymer to make microspheres. This core technology is capable of producing injectable formulations that are biodegradable and release drugs over a period of weeks to months. By formulating drugs using this best-in-class approach, Takeda hopes to apply their microcapsule technology to improve the efficacy and safety of known therapeutics compared to the existing administration methods, while providing alternative treatment options to patients with unmet medical needs. In other words, Takeda makes this   [更多]